Top Story

Prolia reverses cortical bone density loss in women with postmenopausal osteoporosis

March 6, 2015

SAN DIEGO — Treatment with Prolia helped stop and reverse cortical bone density loss at the wrist among women with postmenopausal osteoporosis, according to study findings presented here.

“The skeleton is 80% cortical bone and cortical bone loss contributes importantly to increased fracture risk,” the researchers wrote. “Denosumab has been shown to increase [bone mineral density] at sites of cortical bone, including the 1/3 radius, a skeletal site not responsive to most osteoporosis treatments.”

thumbnail for video 4097735659001 Meeting News CoverageVideo

VIDEO: Wide choice of therapeutic options available for menopause symptoms

March 6, 2015
SAN DIEGO — In this video exclusive, JoAnne E. Manson, MD, DrPh, FACP, FACE, of Brigham and Women’s Hospital and Harvard Medical School in Boston, discusses…
Giuseppe Grande Meeting News Coverage

Soluble urokinase receptor presents biomarker for urogenital tract inflammation

March 6, 2015
SAN DIEGO — Soluble urokinase-type plasminogen activator receptor, or suPAR, a known marker of systemic inflammation, is detectable in semen, according to research…
Meeting News Coverage

Abaloparatide lowers fracture risk in postmenopausal osteoporosis

March 6, 2015
SAN DIEGO — A synthetic form of human parathyroid hormone-related protein, abaloparatide, significantly reduced the rate of new fractures in women with…
Ralph A. DeFronzo Meeting News Coverage

Liraglutide improves weight, HbA1c in overweight/obese adults with type 2 diabetes

March 5, 2015
SAN DIEGO — More patients with overweight and obesity achieved clinically meaningful weight loss with liraglutide 3 mg and 1.8 mg compared with placebo, according…
More News Headlines »
CME
Obesity Consults: Volume 2, Number 2 Obesity Forum 2014 Highlights

Obesity Consults: Volume 2, Number 2
Obesity Forum 2014 Highlights

This activity is supported by educational grants from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc; Eisai, Inc.; Novo Nordisk; Vivus, Inc.

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. Treatment options…
More »
Meeting News Coverage Video
thumbnail for video 4006825234001

The impact of obesity on orthopedic care

January 23, 2015
KOLOA, Hawaii – At Orthopedics Today Hawaii 2015, Thomas P. Schmalzried, MD, discusses the impact the obesity…
More »
CME
Assessing Cornerstones for Successful Weight Loss

Assessing Cornerstones for Successful Weight Loss: Building a Foundation that Really Works

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc.

Obesity has increased dramatically in the past 2 decades and is now considered a health care epidemic in the United…
More »
Current Issues
View the Current Issues
morganatic-roan